NDC 58198-0078 - Zorbium
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 58198-0078
- Package NDCs from labels
- 58198-0078-1, 58198-0078-2
- Manufacturer
- Elanco US Inc. | SpecGx LLC | Ivy Animal Health, Inc.
- Effective date
- 2022-04-25
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Zorbium TM (buprenorphine transdermal solution) | Elanco US Inc. | SpecGx LLC | Ivy Animal Health, Inc. | 2022-04-25 | PRESCRIPTION ANIMAL DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 58198-0078-1 | Zorbium | 0.4 mL in 1 TUBE | SOLUTION | 0.4 | 2 | |
| 58198-0078-1 | Zorbium | 10 in 1 CARTON | SOLUTION | 10 | 2 | |
| 58198-0078-2 | Zorbium | 1 mL in 1 TUBE | SOLUTION | 1 | 2 | |
| 58198-0078-2 | Zorbium | 10 in 1 CARTON | SOLUTION | 10 | 2 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 58198-0078 | ZORBIUM (BUPRENORPHINE) SOLUTION [ELANCO US INC.] | 2 | 4 package rows | 20220429_c00709bf-12fd-40fc-9cff-7a7e7390fcb8.zip |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| SUBLOCADE | BUPRENORPHINE | Indivior Inc. | 6189fb21-9432-45f8-8481-0bfaf3ccde95 | 2026-07-27 | Boxed warning, Warnings, Adverse reactions | 40D3SCR4GZ |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | Bryant Ranch Prepack | 2063d5bf-b3bc-4e73-9046-7e994446ab50 | 2026-06-18 | Warnings, Adverse reactions | 40D3SCR4GZ |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | Bryant Ranch Prepack | fc2755a5-3292-4b49-872d-e22c386a4e44 | 2026-06-11 | Warnings, Adverse reactions | 40D3SCR4GZ |
| Buprenorphine | BUPRENORPHINE | Rhodes Pharmaceuticals LLC | 2738feae-316e-426f-971c-5f142ac01b60 | 2026-05-29 | Boxed warning, Warnings, Adverse reactions | 40D3SCR4GZ |
| Buprenorphine | BUPRENORPHINE | Teva Pharmaceuticals USA, Inc. | 36995ce3-b515-447b-baa9-aa14f84060d8 | 2026-05-12 | Boxed warning, Warnings, Adverse reactions | 40D3SCR4GZ |
| Butrans | BUPRENORPHINE | Knoa Pharma LLC | 794aa355-66de-41b8-aedf-f2c40f6bc664 | 2026-05-01 | Boxed warning, Warnings, Adverse reactions | 40D3SCR4GZ |
| Buprenorphine | BUPRENORPHINE | INGENUS PHARMACEUTICALS, LLC | 186e3be6-8bc0-4bb9-96f5-429d53632f45 | 2026-04-28 | Boxed warning, Warnings, Adverse reactions | 40D3SCR4GZ |
| Buprenorphine | BUPRENORPHINE | Aveva Drug Delivery Systems Inc. | 1aae9b13-7431-42ef-8558-14a2325820e6 | 2026-04-28 | Boxed warning, Warnings, Adverse reactions | 40D3SCR4GZ |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | Lannett Company, Inc. | 14eaa94a-cc8a-4e1e-8cfb-5c976c96c606 | 2026-01-28 | Warnings, Adverse reactions | 40D3SCR4GZ |
| Buprenorphine | BUPRENORPHINE | Amneal Pharmaceuticals NY LLC | c7d079fb-507f-436f-b794-2171b7d97067 | 2026-01-09 | Boxed warning, Warnings, Adverse reactions | 40D3SCR4GZ |
| BRIXADI | BUPRENORPHINE | Braeburn Inc. | 5d8a8fd0-8619-422a-a664-d1d2e8970f48 | 2025-12-31 | Boxed warning, Warnings, Adverse reactions | 40D3SCR4GZ |
| buprenorphine transdermal system | BUPRENORPHINE | Alvogen Inc. | 315284b8-32ab-d34a-ea02-f501c6131bcc | 2025-09-12 | Boxed warning, Warnings, Adverse reactions | 40D3SCR4GZ |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.